NIST offers Vitamin D SRM
This article was originally published in The Tan Sheet
Executive Summary
The National Institute of Standards and Technology offers a new standard reference material, SRM 972, for vitamin D in human serum. The material will help labs more accurately measure patients' vitamin D levels so physicians can diagnose accurately when people are deficient, NIST said. It added physicians are testing vitamin D levels more in part because recent studies link low levels of vitamin D to increased risk of certain diseases (1"The Tan Sheet" June 1, 2009)
You may also be interested in...
More NIST supplement standards on the way
The National Institute of Standards and Technology soon will offer standard reference material and certificates of analysis for a berry suite, including cranberries, bilberries and blueberries, a green tea suite and tocopherols in edible oil. NIST has other dietary supplement materials in the acquisition phase, including St. John's Wort, pomegranate and turmeric, said NIST research chemist Kate Rimmer. NIST prioritizes SRM development based on safety concerns and market share for particular supplements, Rimmer said Nov. 11 at the SupplySide West trade show and conference in Las Vegas. The Department of Commerce agency sells the reference substances to manufacturers looking to develop or calibrate lab validation methods. NIST recently began offering an SRM for vitamin D in human serum (1"The Tan Sheet" Oct. 12, 2009, In Brief)
Lack of Vitamin D may be linked to dementia
Researchers should investigate whether vitamin D deficiency is linked to Alzheimer's disease, says William Grant of the Sunlight, Nutrition and Health Research Center. He explains in the May 2009 issue of the Journal of Alzheimer's Disease that low serum levels of 25-hydroxyvitamin D are associated with cardiovascular disease, diabetes and oral health - all of which are risk factors for or precede dementia
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.